Archford Capital Strategies’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $65.3K | Hold |
52,694
| – | – | 0.01% | 320 |
|
|
2025
Q1 | $62.2K | Hold |
52,694
| – | – | 0.01% | 289 |
|
|
2024
Q4 | $96.4K | Sell |
52,694
-1
| -0% | -$2 | 0.01% | 265 |
|
|
2024
Q3 | $108K | Hold |
52,695
| – | – | 0.02% | 252 |
|
|
2024
Q2 | $72.2K | Sell |
52,695
-18,063
| -26% | -$24.7K | 0.01% | 256 |
|
|
2024
Q1 | $265K | Buy |
70,758
+50,734
| +253% | +$190K | 0.04% | 232 |
|
|
2023
Q4 | $196K | Sell |
20,024
-53,660
| -73% | -$526K | 0.04% | 246 |
|
|
2023
Q3 | $615K | Sell |
73,684
-162
| -0.2% | -$1.35K | 0.12% | 168 |
|
|
2023
Q2 | $952K | Sell |
73,846
-393
| -0.5% | -$5.07K | 0.18% | 133 |
|
|
2023
Q1 | $814K | Buy |
74,239
+760
| +1% | +$8.33K | 0.17% | 138 |
|
|
2022
Q4 | $601K | Sell |
73,479
-9,183
| -11% | -$75.1K | 0.14% | 171 |
|
|
2022
Q3 | $480K | Buy |
82,662
+8,089
| +11% | +$47K | 0.12% | 184 |
|
|
2022
Q2 | $330K | Buy |
74,573
+1,278
| +2% | +$5.66K | 0.08% | 217 |
|
|
2022
Q1 | $693K | Buy |
73,295
+1,458
| +2% | +$13.8K | 0.15% | 150 |
|
|
2021
Q4 | $1.47M | Sell |
71,837
-1,209
| -2% | -$24.7K | 0.34% | 77 |
|
|
2021
Q3 | $1.87M | Buy |
73,046
+326
| +0.4% | +$8.33K | 0.44% | 53 |
|
|
2021
Q2 | $2.54M | Buy |
72,720
+2,588
| +4% | +$90.5K | 0.64% | 33 |
|
|
2021
Q1 | $2.3M | Buy |
70,132
+6,032
| +9% | +$198K | 0.61% | 36 |
|
|
2020
Q4 | $2.35M | Buy |
64,100
+7,000
| +12% | +$257K | 0.54% | 50 |
|
|
2020
Q3 | $564K | Buy |
+57,100
| New | +$564K | 0.15% | 162 |
|